COAG (Hemab Therapeutics Holdings) Accounts Payable: $5.73 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COAG Hemab Therapeutics Holdings Inc COAG
11 GF Score
Price $49.66
! 2 Warning Signs
View Full Analysis

What is Hemab Therapeutics Holdings Accounts Payable?

Hemab Therapeutics Holdings COAG -4.44% 11 Accounts Payable is $5.73 Mil as of Dec. 2025. GuruFocus rates COAG with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Hemab Therapeutics Holdings's Accounts Payable for the quarter that ended in Dec. 2025 was $5.73 Mil.

Hemab Therapeutics Holdings's quarterly Accounts Payable increased from . 20 ($0.00 Mil) to Dec. 2024 ($3.16 Mil) and increased from Dec. 2024 ($3.16 Mil) to Dec. 2025 ($5.73 Mil).

Hemab Therapeutics Holdings's annual Accounts Payable increased from . 20 ($0.00 Mil) to Dec. 2024 ($3.16 Mil) and increased from Dec. 2024 ($3.16 Mil) to Dec. 2025 ($5.73 Mil).

Hemab Therapeutics Holdings Accounts Payable Related Terms

Hemab Therapeutics Holdings Accounts Payable Historical Data

* Premium members only.

The historical data trend for Hemab Therapeutics Holdings's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemab Therapeutics Holdings Accounts Payable Chart

Hemab Therapeutics Holdings Annual Data
Trend Dec24 Dec25
Accounts Payable
3.16 5.73

Hemab Therapeutics Holdings Semi-Annual Data
Dec24 Dec25
Accounts Payable 3.16 5.73
COAG
11GF Score
Hemab Therapeutics Holdings Inc COAG
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hemab Therapeutics Holdings Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $5.73 Mil mean?
Hemab Therapeutics Holdings (COAG) has a Accounts Payable of $5.73 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Hemab Therapeutics Holdings and its competitors.
Is Hemab Therapeutics Holdings' Accounts Payable too high?
Hemab Therapeutics Holdings' current Accounts Payable is $5.73 Mil. Overall, Hemab Therapeutics Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Hemab Therapeutics Holdings' Accounts Payable compare to ZLAB and SLS?
Hemab Therapeutics Holdings' Accounts Payable of $5.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Hemab Therapeutics Holdings and its competitors. Hemab Therapeutics Holdings's current Accounts Payable is $5.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemab Therapeutics Holdings stock overvalued right now?
Hemab Therapeutics Holdings (COAG) has a current Accounts Payable of $5.73 Mil. The current Accounts Payable is $5.73 Mil. Hemab Therapeutics Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Hemab Therapeutics Holdings (COAG), the current Accounts Payable is $5.73 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemab Therapeutics Holdings Business Description

Address 101 Main Street, Suite 1220, Cambridge, MA, USA, 02142
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
11GF Score

Get the complete analysis for COAG

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$49.66
Price